Advertisement

Journal of Gastrointestinal Cancer

, Volume 46, Issue 4, pp 356–364 | Cite as

Neuroendocrine Carcinoma of Gall Bladder: A Series of 19 Cases with Review of Literature

  • Meenakshi Kamboj
  • Jatin Sundersham Gandhi
  • Gurudutt Gupta
  • Anila Sharma
  • Sunil Pasricha
  • Anurag Mehta
  • D. Chandragouda
  • Rupal Sinha
Original Research

Abstract

Background

Neuroendocrine neoplasms of the gall bladder (GB) are rare tumors classified as grade 1 and 2 neuroendocrine tumor (NET), neuroendocrine carcinoma (large cell or small cell type), and mixed adeno-neuroendocrine carcinoma (MANEC). Primary neuroendocrine carcinomas (NEC) of GB are rare with grave prognosis not withstanding radical surgical treatment. Chemotherapy forms the primary management due to the advanced stage at presentation, as complete surgical resection is generally not possible. The overall median survival is 4–6 months despite aggressive management. Only 73 cases of small cell carcinoma (SCC) and 10 cases of large cell neuroendocrine carcinoma (LCNEC) have been reported in English literature till now. We present a series of 19 cases of NEC of GB with their pathological and clinical features and response to treatment.

Objective

The objective of this study was to evaluate NECs of the GB for their clinical behavior, prognosis, and treatment outcome in terms of survival and to segregate NECs into further subcategories, that is 20–50 % and >50 %, based on MIB-1 index.

Methods

We retrospectively searched the clinical and pathological database over 2.5 years (January 2012 to June 2014) through existing electronic hospital medical records to collect cases of NEC arising in GB. A total of 447 cases of gall bladder pathologies were analyzed, of which 19 cases were diagnosed as NEC. All relevant investigations were documented and response to treatment/therapy was evaluated clinically and radiologically. Tumor specimen was obtained by fine-needle aspiration cytology and/or biopsy and classified using the latest World Health Organisation (WHO) classification (2010) via cytopathologic, histopathologic, and immunohistochemical visage.

Results

Nineteen patients diagnosed as NEC of GB were evaluated in the study, with 16 having SCC, 2 having LCNEC, and 1 with MANEC. All patients presented in advanced clinical stage III or IV, along with distant metastasis and showed progressive disease during therapy. Ki67 index was between 20 and 50 % in 5 cases and >50 % in 8 cases. Follow-up was available in 14 cases with a median survival of 3 months, and 2 of these patients capitulated to their illness, before commencement of treatment. The remaining 5 cases were lost to follow-up. Out of these, 2 had deranged liver function test and no chemotherapy could be administered, and the other 3 refused treatment.

Conclusions

NECs are aggressive with generally poor prognosis, characterized by insidious onset and advanced clinical stage of presentation. A radical approach to treatment with chemotherapy is the best form of palliation. Role of radiotherapy remains undefined due to paucity of data.

Keywords

Gall bladder Neuroendocrine carcinoma Small and large cell type 

Notes

Conflicts of Interest

The authors declare that they have no competing interests.

References

  1. 1.
    Mezi S, Petrozza V, Schillaci O, La Torre V, Cimadon B, Leopizzi M, et al. Neuroendocrine tumors of the gallbladder: a case report and review of the literature. J Med Case Rep. 2011;5:334.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Eltawil KM, Gustafsson BI, Kidd M, Modlin IM. Neuroendocrine tumors of the gall bladder: an evaluation and reassessment of management strategy. J Clin Gastroenterol. 2010;44:687–95.PubMedGoogle Scholar
  3. 3.
    Komminoth P, Arnold R, Capella C, Klimstra DS, Kloppel G, Rindi G, et al. Neuroendocrine neoplasms of the gallbladder and extrahepatic bile ducts. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. World health organization of tumours: pathology and genetics of tumours of the digestive system. 4th ed. Lyon (France): International Agency for Research on Cancer (IARC); 2010. p. 274–6.Google Scholar
  4. 4.
    Tunio AM, AlAsiri M, Ali AMF, AlSaeed EF, Shuja M, Fatani H. Distal humerus as delayed site of metastasis from small cell carcinoma of gallbladder. Gastrointest Med. 2013;2013:1–4.Google Scholar
  5. 5.
    Theise ND. Liver and gallbladder. In: Kumar V, Abbas AK, Aster JC, editors. Pathologic basis of disease. 9th ed. Philadelphia: Saunders, an Imprint of Elsevier; 2014. p. 821–81.Google Scholar
  6. 6.
    Iwasa S, Morizane C, Okusaka T, Ueno H, Ikeda M, Kondo S, et al. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol. 2010;40:313–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Lee JM, Hwang S, Lee SG, Lee YJ, Park KM, Kim KH, et al. Neuroendocrine tumors of the gallbladder: twelve cases in a single institution. Hepato-Gastroenterology. 2010;57:1064–8.PubMedGoogle Scholar
  8. 8.
    Moskal TL, Zhang PJ, Nava HR. Small cell carcinoma of the gallbladder. J Surg Oncol. 1999;70:54–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Mahipal A, Gupta S. Small-cell carcinoma of the gallbladder: report of a case and literature review. Gastrointest Cancer Res. 2011;4:135–6.PubMedCentralPubMedGoogle Scholar
  10. 10.
    Maitra A, Tascilar M, Hruban RH, Offerhaus GJ, Albores–Saavedra J. Small cell carcinoma of the gallbladder: a clinicopathologic, immunohistochemical, and molecular pathology study of 12 cases. Am J Surg Pathol. 2001;25:595–601.CrossRefPubMedGoogle Scholar
  11. 11.
    Uribe-Uribe NO, Jimenez-Garduño AM, Henson DE, Albores-Saavedra J. Paraneoplastic sensory neuropathy associated with small cell carcinoma of the gallbladder. Ann Diagn Pathol. 2009;13:124–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15:529–53.CrossRefPubMedGoogle Scholar
  13. 13.
    Papotti M, Cassoni P, Sapino A, Passarino G, Krueger JE, Albores-Saavedra J. Large cell neuroendocrine carcinoma of the gallbladder: report of two cases. Am J Surg Pathol. 2000;24:1424–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Janson ET, Sorbye H, Welin S, Federspiel B, Gronbaek H, Hellman P, et al. Nordic guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol. 2010;49:740–56.CrossRefPubMedGoogle Scholar
  15. 15.
    Pavithran K, Prabhash K, Hazarika D, Doval DC. Neuroendocrine carcinoma of gallbladder: report of 2 cases. Hepatobiliary Pancreat Dis Int. 2005;4:144–6.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Meenakshi Kamboj
    • 1
  • Jatin Sundersham Gandhi
    • 1
  • Gurudutt Gupta
    • 1
  • Anila Sharma
    • 1
  • Sunil Pasricha
    • 1
  • Anurag Mehta
    • 1
  • D. Chandragouda
    • 2
  • Rupal Sinha
    • 3
  1. 1.Department of Histopathology and CytopathologyRajiv Gandhi Cancer Institute and Research CentreDelhiIndia
  2. 2.Department of Medical OncologyRajiv Gandhi Cancer Institute and Research CentreDelhiIndia
  3. 3.Department of ResearchRajiv Gandhi Cancer Institute and Research CentreNew DelhiIndia

Personalised recommendations